ESMO Open | ScienceGate

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

ESMO Open ◽

10.1016/j.esmoop.2021.100366 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100366

Author(s):

T. Samaille ◽

C. Moreau Bachelard ◽

E. Coquan ◽

P. du Rusquec ◽

X. Paoletti ◽

...

Keyword(s):

Clinical Trials ◽

Cancer Patients ◽

Advanced Cancer ◽

Progression Free Survival ◽

Advanced Cancer Patients ◽

Free Survival ◽

Median Progression Free Survival

Download Full-text

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

ESMO Open ◽

10.1016/j.esmoop.2021.100341 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100341

Author(s):

Y. Cao ◽

S. Qin ◽

S. Luo ◽

Z. Li ◽

Y. Cheng ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell

Download Full-text

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

ESMO Open ◽

10.1016/j.esmoop.2021.100314 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100314

Author(s):

M.M. Javle ◽

D.-Y. Oh ◽

M. Ikeda ◽

W.-P. Yong ◽

K. Hsu ◽

...

Keyword(s):

Biliary Tract ◽

Phase Ii ◽

Biliary Tract Cancer ◽

Phase Ii Study ◽

Second Line ◽

Tract Cancer ◽

Randomized Phase Ii

Download Full-text

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management

ESMO Open ◽

10.1016/j.esmoop.2021.100338 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100338

Author(s):

P. Vallerio ◽

A. Orenti ◽

F. Tosi ◽

M. Maistrello ◽

M. Palazzini ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Cardiovascular Events ◽

Kinase Inhibitors ◽

Real Life ◽

Major Adverse Cardiovascular Events ◽

Life Study ◽

Proactive Management ◽

Real Life Study

Download Full-text

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

ESMO Open ◽

10.1016/j.esmoop.2021.100353 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100353

Author(s):

O. Molinier ◽

B. Besse ◽

F. Barlesi ◽

C. Audigier-Valette ◽

S. Friard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Real World ◽

Small Cell ◽

Small Cell Lung ◽

Term Survival ◽

Long Term Survival ◽

Real World Evidence

Download Full-text

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers

ESMO Open ◽

10.1016/j.esmoop.2021.100334 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100334

Author(s):

R. Zhong ◽

X. Ling ◽

S. Cao ◽

J. Xu ◽

B. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Dendritic Cell ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Safety And Efficacy

Download Full-text

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit

ESMO Open ◽

10.1016/j.esmoop.2021.100344 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100344

Author(s):

G. Pentheroudakis ◽

G. Curigliano ◽

C. Zielinski

Keyword(s):

Clinical Practice ◽

Clinical Practice Guidelines ◽

Practice Guidelines ◽

New Approaches

Download Full-text

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

ESMO Open ◽

10.1016/j.esmoop.2021.100355 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100355

Author(s):

C. Gridelli ◽

S. Peters ◽

T. Mok ◽

P.M. Forde ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Expert Panel ◽

Performance Status ◽

Small Cell ◽

International Expert ◽

Small Cell Lung ◽

First Line ◽

Ecog Performance Status ◽

Lung Cancer Patients

Download Full-text

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

ESMO Open ◽

10.1016/j.esmoop.2021.100336 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100336

Author(s):

M. Palmeri ◽

J. Mehnert ◽

A.W. Silk ◽

S.K. Jabbour ◽

S. Ganesan ◽

...

Keyword(s):

Microsatellite Instability ◽

Real World ◽

Real World Application ◽

Mutational Burden ◽

Tumor Mutational Burden

Download Full-text

Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: a multistate model study

ESMO Open ◽

10.1016/j.esmoop.2021.100363 ◽

2022 ◽

Vol 7 (1) ◽

pp. 100363

Author(s):

S.F. Lee ◽

B.A. Vellayappan ◽

L.C. Wong ◽

C.L. Chiang ◽

S.K. Chan ◽

...

Keyword(s):

Cardiovascular Diseases ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Multistate Model ◽

Large B Cell Lymphoma ◽

Model Study ◽

Long Term Survivors ◽

Large B Cell

Download Full-text

ESMO Open
Latest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Bmj

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: a multistate model study

Export Citation Format

ESMO OpenLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Bmj

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Cardiovascular diseases among diffuse large B-cell lymphoma long-term survivors in Asia: a multistate model study

ESMO Open
Latest Publications